Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.02, for a total transaction of $70,140.00. Following the transaction, the chief technology officer owned 83,865 shares in the company, valued at approximately $840,327.30. This trade represents a 7.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Candel Therapeutics Trading Down 4.1%

Shares of CADL stock opened at $9.88 on Thursday. The stock has a 50-day moving average of $8.24 and a 200-day moving average of $6.46. Candel Therapeutics, Inc. has a 1-year low of $4.35 and a 1-year high of $11.36. The stock has a market cap of $723.91 million, a price-to-earnings ratio of -10.08 and a beta of -0.52. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34.

Candel Therapeutics (NASDAQ:CADL) last released its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16. On average, equities research analysts forecast that Candel Therapeutics, Inc. will post -0.97 earnings per share for the current year.

Analyst Ratings Changes

CADL has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating for the company. Citigroup dropped their price objective on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of Candel Therapeutics in a report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its holdings in shares of Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Candel Therapeutics by 361.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after purchasing an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics in the 4th quarter valued at about $51,000. ProShare Advisors LLC bought a new stake in Candel Therapeutics in the fourth quarter valued at approximately $59,000. Finally, Invesco Ltd. bought a new stake in Candel Therapeutics during the 1st quarter valued at $59,000. 13.93% of the stock is currently owned by hedge funds and other institutional investors.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.